Related Experiment Video
Updated: May 11, 2026
10:32
Optimized Protocols for Mycobacterium leprae Strain Management: Frozen Stock Preservation and Maintenance in Athymic Nude Mice
Published on: March 23, 2014
Fixed-duration therapy in leprosy: limitations and opportunities.
Munisamy Malathi1, Devinder Mohan Thappa
1Department of Dermatology and STD, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, India.
Indian Journal of Dermatology
|May 30, 2013
Summary
Multidrug therapy (MDT) has made leprosy curable, but debates continue regarding the optimal treatment duration. Balancing patient cure with public health needs is crucial for leprosy eradication efforts.
Area of Science:
- Medical Microbiology
- Public Health
- Infectious Diseases
Background:
- Leprosy is a curable infectious disease due to multidrug therapy (MDT).
- MDT has significantly impacted global leprosy control, advancing towards eradication.
- Treatment regimens, particularly duration, have evolved, sparking debate.
Purpose of the Study:
- To review the limitations and opportunities of fixed-duration (FD) therapy for leprosy.
- To discuss controversies surrounding shortened treatment durations versus relapse risks.
- To highlight newer multidrug therapy (MDT) regimens in leprosy management.
Main Methods:
- Literature review of MDT regimens and treatment durations for leprosy.
- Analysis of the advantages and disadvantages of fixed-duration (FD) therapy.
- Discussion of public health perspectives versus academic/private practitioner preferences.
Main Results:
- Fixed-duration (FD) therapy faces challenges with acceptance among some medical professionals.
- Public health perspectives favor shorter, cost-effective treatment for elimination programs.
- Balancing individual cure rates with societal protection remains a key challenge.
Conclusions:
- Optimizing leprosy treatment requires balancing patient cure with public health feasibility.
- Further research into newer MDT regimens and their efficacy is warranted.
- Effective leprosy control necessitates a pragmatic approach to treatment duration.
Related Concept Videos
01:28Pulmonary Tuberculosis V
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
01:23Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration
Drug elimination from the body primarily occurs through metabolic and excretion pathways. Hepatic metabolism transforms lipophilic drugs into hydrophilic forms for excretion, typically via enzymatic processes classified as phase I (modification) and phase II (conjugation). Renal excretion eliminates drugs and metabolites through filtration and secretion in the kidneys. Impairment in liver or kidney function can hinder these processes, delaying drug clearance and extending the drug’s half-life.
01:26Psychosis: Goals of Pharmacotherapy
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
01:29Pulmonary Tuberculosis I
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
01:19Modified-Release Drug Delivery Systems: Overview
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.